State Street Corp Acquires 216,484 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

State Street Corp boosted its holdings in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 10.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,331,433 shares of the biopharmaceutical company’s stock after acquiring an additional 216,484 shares during the period. State Street Corp owned 4.09% of Agios Pharmaceuticals worth $103,586,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Erste Asset Management GmbH purchased a new position in Agios Pharmaceuticals during the third quarter valued at $97,199,000. Caligan Partners LP increased its holdings in shares of Agios Pharmaceuticals by 12.6% during the third quarter. Caligan Partners LP now owns 579,717 shares of the biopharmaceutical company’s stock valued at $25,757,000 after acquiring an additional 65,006 shares in the last quarter. Verition Fund Management LLC bought a new position in shares of Agios Pharmaceuticals during the third quarter valued at $315,000. Vestal Point Capital LP purchased a new position in shares of Agios Pharmaceuticals in the 3rd quarter worth about $33,767,000. Finally, Summit Partners Public Asset Management LLC bought a new position in Agios Pharmaceuticals in the 3rd quarter worth about $4,520,000.

Insider Buying and Selling at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, CFO Cecilia Jones sold 2,542 shares of the company’s stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $49.03, for a total transaction of $124,634.26. Following the completion of the sale, the chief financial officer now directly owns 20,158 shares of the company’s stock, valued at approximately $988,346.74. This represents a 11.20 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 4.93% of the stock is owned by corporate insiders.

Agios Pharmaceuticals Price Performance

AGIO stock opened at $38.97 on Monday. Agios Pharmaceuticals, Inc. has a 1 year low of $20.96 and a 1 year high of $62.58. The company has a market cap of $2.22 billion, a P/E ratio of 3.43 and a beta of 0.80. The stock’s fifty day moving average price is $50.02 and its 200-day moving average price is $46.76.

Wall Street Analysts Forecast Growth

AGIO has been the topic of several analyst reports. Royal Bank of Canada upped their target price on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 10th. StockNews.com raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, November 9th. Leerink Partnrs lowered Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, September 27th. Raymond James reaffirmed an “outperform” rating and set a $51.00 price target on shares of Agios Pharmaceuticals in a report on Thursday, October 10th. Finally, Scotiabank lifted their price objective on Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a report on Monday, December 9th. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $56.33.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.